The European Scleroderma Trials and Research Group (EUSTAR) revised activity index scale, known as EUSTAR-AI, is the best tool for predicting the short-term risk of disease progression and severe organ involvement in scleroderma (SSc) patients diagnosed within the last five years, a study reports. It had a better predictive…
News
Use of vasodilators — medications that trigger the widening and relaxing of blood vessels — may help to prevent heart problems in people with systemic scleroderma, a study suggests. Low-dose aspirin was also found to offer some protection against some forms of cardiac disease, its researchers said, recommending more…
Uric Acid Levels in Blood Predicts PAH Risk and Outcomes in Scleroderma Patients, Study Reports
Higher than usual serum levels of uric acid are linked to a greater risk of pulmonary arterial hypertension (PAH) among people with scleroderma, according to new research. Its findings also showed an association between higher levels of this blood biomarker and both disease severity and mortality in scleroderma-associated PAH…
Patient-reported symptoms — specifically those related to blood vessel, skin, and lung function — may be used to indicate changes in disease activity in people with systemic sclerosis (SSc), an Australian study suggests. The study, “Can patient-reported symptoms be used to measure disease activity in systemic…
Imagine living your whole life with a painful disease so rare that only 25 others worldwide have what you have. And that you’re one of just six such people who’ve made it to adulthood. Neena Nizar doesn’t have to imagine. The 41-year-old English professor at Metro Community College in Elkhorn,…
Close Monitoring Needed for SSc Patients With Rare Type of Interstitial Lung Disease, Study Shows
Evidence of pleuroparenchymal fibroelastosis (PPFE) — a rare type of interstitial lung disease — in people with systemic sclerosis (SSc) carries a negative prognosis, a study shows. Therefore, SSc patients with PPFE should be closely monitored and receive regular follow-up by their healthcare team. The study, titled “…
Loss of muscle mass and strength — known as sarcopenia — may affect up to 55% of patients with systemic sclerosis (SSc), a study suggests. Moreover, sarcopenia was found to be associated with several clinical and nutritional parameters of disease severity. The study, “Sarcopenia in systemic sclerosis: the impact…
Levels of a pro-inflammatory signaling molecule, called interleukin (IL)-6, are significantly high in skin lesions and blood samples of patients with systemic sclerosis (SSc), especially among those with diffuse cutaneous SSc, a small Japanese study reports. The study, “IL-16 expression is increased in the skin and sera of…
Patients with scleroderma show more frequent and/or stronger immune responses against the human cytomegalovirus (HCMV), suggesting a role in disease development, according to new research. The findings also revealed a correlation between these viral responses and scleroderma-associated autoantibodies. The study, “A comprehensive analysis of antigen-specific antibody…
Systemic sclerosis (SSc) patients with elevated protein in their urine (proteinuria) who are using angiotensin-converting enzyme (ACE) inhibitors (ACEi) are at higher risk of developing scleroderma renal crisis (SRC), a retrospective study shows. The study, “Systemic sclerosis mediations and risk of scleroderma renal crisis,” was published in the…
Recent Posts
- New anti-scarring pill shows encouraging safety in early trial
- No-touch light test may help in monitoring scleroderma skin changes
- Ultrasound technique may help detect muscle changes earlier in SSc
- Study ties acid reflux, bloating to fatigue in scleroderma
- Study links cancer in scleroderma to timing and autoantibodies
- Routine blood test may help flag lung disease risk in diffuse SSc, study says
- Nearly half with SSc consider facial cosmetic therapy, survey finds
- Inhaled therapy for Raynaud’s attacks put on FDA fast track
- Vitamin B3 may improve blood vessels in scleroderma-related Raynaud’s
- John Stamos to be honored for longtime support of scleroderma research